• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

DASH Diet, Weight Loss, Exercise and Other Nondrug Strategies to Manage Hypertension

Slideshow

Find out how effective these 3 and 5 additional ACC/AHA-recommended non-drug interventions are at reducing BP (in mm Hg) in adults with hypertension and with normal BP.

The 2017 American College of Cardiology/American Heart Association hypertension detection and treatment guidelines ​ recommend nonpharmacologic interventions to help prevent and manage hypertension in most adults, hypertension now defined as blood pressure of 130-139/80-90 mm Hg.

According to the ACC/AHA guideline, the interventions in the slide show that follows may be sufficient to prevent hypertension as well as to help individuals with stage 1 hypertension meet blood pressure goals; they are integral to management of stage 2 hypertension in tandem with medication and they are all recommended as the foundation of individual and population approaches to reducing risk of BP-related cardiovascular disease.

Each slide in this guideline topline presents the type of intervention, recommended dose, and expected reduction in BP in adults with hypertension and those with normotension.

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2024 MJH Life Sciences

All rights reserved.